Trial Profile
Cynergy - The CYPHER-NEVO Registry. An Observational Registry, to Evaluate the Safety and Performance of the NEVO Sirolimus-eluting Coronary Stent in Routine Clinical Practice, and to Compare Its Safety and Performance With the CYPHER Select Plus Sirolimus-eluting Coronary Stent (SES).
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 15 Jul 2011
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis; Myocardial infarction
- Focus Therapeutic Use
- Acronyms CYNERGY
- Sponsors Cordis Corporation
- 11 Jul 2011 Planned End Date changed from 1 Apr 2015 to 1 Dec 2011 as reported by ClinicalTrials.gov.
- 11 Jul 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 09 Sep 2010 Planned end date changed from 1 Apr 2014 to 1 Apr 2015 as reported by ClinicalTrials.gov.